Hence, measuring the levels of TAp73, SMAD4 and/or pERK could help to predict whether TGF-β preferentially uses an oncogenic or a tumor-suppressive pathway in a given patient and at a specific time. This evidence concerns the gene EIF2AK3 and neoplasm.